{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.6","upperLimit":"7.4","value":"6.5"},{"groupId":"OG001","lowerLimit":"5.7","upperLimit":"7.0","value":"6.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"200"}],"units":"Participants"}],"description":"Time to Treatment Failure (TTF) is defined as the time from the date of randomisation to discontinuation of protocol treatment for any reason (including progression of disease, death, discontinuation of at least one of the drugs consisting the treatment combination due to any reason, such as toxicity or refusal). Censoring will occur at the last follow-up date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Atezolizumab 1200mg intravenously on day 1 every 3 weeks plus bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG000","title":"Atezolizumab Plus Bevacizumab Plus Chemotherapy"},{"description":"Bevacizumab 15mg/kg intravenously on day 1 every 3 weeks plus 4-6 cycles of carboplatin AUC 5 plus pemetrexed 500mg/m\\^2 intravenously on day 1 every 3 weeks","id":"OG001","title":"Bevacizumab Plus Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"Efficacy population (Intention-To-Treat cohort of all randomised patients)","reportingStatus":"POSTED","timeFrame":"From randomization until discontinuation of protocol treatment for any reason, up to 52 months.","title":"Time to Treatment Failure (TTF)","type":"SECONDARY","unitOfMeasure":"months"}